SCHEMBL10173634

SCHEMBL10173634

CCNC(=O)c1cc2nc(Nc3c(Cl)cncc3Cl)n(C)c2nc1OCCF

nearest known ligand 0.41

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
PTGES O14684 15/20 0.41
RAF1 P04049 1/20 0.36
BRAF P15056 1/20 0.36
PDE4B Q07343 1/20 0.34
CNR1 P21554 2/20 0.33
CNR2 P34972 1/20 0.33
PIM1 P11309 1/20 0.33
BAD Q92934 1/20 0.33
PIM2 Q9P1W9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10173645 0.91 PTGES (0.41) PTGESRAF1BRAFPDE4BCNR1
SCHEMBL10173638 0.88 PTGES (0.51) PTGES
SCHEMBL2685977 0.87 PTGES (0.40) PTGES
SCHEMBL10173606 0.87 PTGES (0.37) PTGESRAF1BRAFPDE4BCNR1
SCHEMBL2696597 0.85 PTGES (0.46) PTGESRAF1BRAF
SCHEMBL10173631 0.84 CNR1 (0.43) PTGESCNR1CNR2
SCHEMBL2685142 0.83 PTGES (0.51) PTGES
SCHEMBL10173651 0.82 PTGES (0.42) PTGESCNR1CNR2
SCHEMBL2686116 0.82 PTGES (0.48) PTGES
SCHEMBL2686120 0.82 PTGES (0.48) PTGES

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703796-B2 3H-imidazo [4, 5-B] pyridine-6-carboxamides as anti-inflammatory agents BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-04-22 US disclosed
US-20120115902-A1 3H-Imidazo [4, 5-B] Pyridine- 6 -Carboxamides As Anti-Inflammatory Agents BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115902-A1 3H-Imidazo [4, 5-B] Pyridine- 6 -Carboxamides As Anti-Inflammatory Agents MAP4, MAPRE2, IL4 PTGES 132/4885RAF1 1300/4885BRAF 868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.